跳至主導覽 跳至搜尋 跳過主要內容

Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants

  • Shih Cheng Yang
  • , Chuan Mo Lee
  • , Tsung Hui Hu
  • , Jing Houng Wang
  • , Sheng Nan Lu
  • , Chao Hung Hung
  • , Chi Sin Changchien
  • , Chien Hung Chen*
  • *此作品的通信作者
  • Chang Gung University

研究成果: 期刊稿件 › 文章 › 同儕審查

37 引文 斯高帕斯(Scopus)

摘要

Objectives: This study investigated the influence of virological response (VR) to entecavir on clinical liver disease progression in nucleos(t)ide analogue (NA)-naive and -experienced patients. Methods: We investigated 487 chronic hepatitis B patients (323 NA-naive, 164 NA-experienced) treated with entecavir monotherapy for at least 12 months. VR was defined as hepatitis B virus DNA level ≤ 300 copies/mL during entecavir therapy. Clinical events were defined as hepatic decompensation, hepatocellular carcinoma (HCC), death and liver transplantation. Results: Of the 487 patients, 49 developed clinical events during entecavir treatment. Of those, 36 developed HCC. For all patients, Cox regression analysis showed that age, baseline cirrhosis, alanine aminotransferase level ≤ 200 U/L, albumin level and no VR during entecavir treatment were independent predictors for clinical events and HCC development. However, the benefit of VR to entecavir was significant for clinical events and HCC only in NA-experienced patients, but not in NA-naive patients. For the further analysis of the different subgroups of NAexperienced patients, the benefit of VR to entecavir was significant for clinical events or HCC only in patients with prior lamivudine- or adefovir-resistant mutants, but not in NA-experienced patients who had never developed lamivudine- or adefovir-resistant mutants. VR at month 12 (but not early VR at month 6) remained a significant predictor associated with the development of clinical events and HCC in NA-experienced patients. Conclusions: VR to entecavir was associated with a reduced risk of clinical events and HCC in NA-experienced patients, particularly in those who had prior lamivudine- or adefovir-resistant mutant.

原文英語
文章編號dkt147
頁(從 - 到)2154-2163
頁數10
期刊Journal of Antimicrobial Chemotherapy
卷68
發行號9
DOIs
出版品狀態已出版 - 09 2013

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants」主題。共同形成了獨特的指紋。

引用此